An interventional study of Deep Brain Stimulation (DBS) in Parkinson Disease, sponsored by University of Florida. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-15.
Sponsored by University of Florida · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Parkinson Disease by University of Florida — 5 open to participants now, 6 under way, none of them phase 3. Parkinson Disease · University of Florida.
Among the 41 studies in Parkinson Disease by University of Florida, this one is the 8th largest by planned enrollment of the 33 interventional ones that give a count, is one of 2 that started in 2025, is one of 25 with no phase, and was the 37th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →5 of the 41 studies in Parkinson Disease by University of Florida are open now, in 1 country. Recruiting first, the newest first:
University of Florida · Sites in United States
Ages 40–75
University of Florida · Sites in United States
Ages 18–80
University of Florida · Sites in United States
Ages 21–89
University of Florida · Sites in United States
Ages 45–85
By country, each count listing its studies:
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 4 · Phase 4 1
First in 2004; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 35 across the 33 interventional studies, 30 across the 8 observational. Of the 34 that completed or were terminated, 9 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Florida is the lead sponsor of 1,290 studies on the registry; 202 are open to participants now.
Of its 181 completed or terminated interventional studies of FDA-regulated products, 143 (79%) have results posted.
3 of the studies in Parkinson Disease by University of Florida that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07348705University of FloridaElectrophysiology-based DBS Programming for PD | 2027-01-15 |
| NCT05913687University of FloridaAutomated Imaging Differentiation of Parkinsonism | 2027-03-31 |
| NCT06911229University of FloridaNeurophysiology of Locomotor Adaptation and Freezing of Gait in Parkinson's Disease | 2027-07-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 41 studies in Parkinson Disease by University of Florida, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Locomotor adaptation will be studied using an established split-belt treadmill paradigm, consisting of baseline (1:1 speed ratio), split-belt adaptation (2:1) and post-adaptation (1:1) walking. Split-belt walking will be performed under DBS ON and DBS OFF conditions, while off-medication.
We will test the hypotheses that DBS can facilitate split-belt walking adaptation with DBS ON compared with DBS OFF.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
DBS will be turned on
Device: Deep Brain Stimulation (DBS)
DBS will be turned off
Patients will receive DBS in the clinically-optimized setting.
Step length rate of adaptation
The rate of adaptation in step length asymmetry is estimated by fitting an exponential decay function to step length asymmetry over the first 100 strides in adaptation.
Time frame: 1 hour
Step length magnitude of adaptation
The magnitude of adaptation in step length asymmetry is calculated as the mean difference in step length asymmetry between early and late adaptation.
Time frame: 1 hour
Step length after-effects
The after-effect in step length asymmetry is calculated as the mean difference in step length asymmetry between baseline and early post-adaptation.
Time frame: 1 hour
Started Oct 2025 (actual). Primary completion is estimated for Jul 2027, 21 months after the start.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 21 months is below that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.